Can't Afford Mounjaro Right Now? Here's What to Weigh Up

What the trial evidence says about value, not just price

Before thinking about affordability, it helps to understand what the medicine is actually being priced against. In the SURMOUNT-1 trial, involving around 2,500 adults with obesity, tirzepatide at its highest dose produced an average body-weight reduction of around 20–21% over 72 weeks, figures cited by NICE's technology appraisal TA1026, which recommended tirzepatide for NHS use in December 2024. That level of clinical effect, in a medicine that also requires regular prescriber oversight, specialist dispensing and a cold-chain supply chain, is part of what drives the cost. The evidence base is strong, and that strength is part of why the medicine attracts the price it does. None of that makes the barrier less real, but it does reframe the question from "is this overpriced?" to "is this the right time, and the right route, for me?"

A question our prescribers hear most weeks is whether someone should wait until they can manage the cost more comfortably, or whether the health risks of not treating outweigh the financial stress. There's no single answer. What the evidence does suggest is that stopping and restarting treatment repeatedly is less effective than a sustained period of use alongside lifestyle changes, so timing and financial stability both matter. You can explore more about the treatment and how it works on the Mounjaro treatment page, which covers mechanism, eligibility and what a private prescription includes.

NHS access: who qualifies and how the phased rollout actually works

The honest answer for many people who can't afford private tirzepatide is: check whether you qualify on the NHS first. NICE's recommendation covers adults with a BMI of 35 or above who also have at least a qualifying number of weight-related health conditions, with that threshold reduced by 2.5 kg/m² for some ethnic backgrounds. The rollout is phased by cohort. From around June 2025, the NHS began prescribing to people with a BMI of 40 or above with four or more of five specified conditions. From June 2026, eligibility broadened to include people with a BMI of 35–39.9 with four or more of those conditions. Further cohorts are expected from around March 2027. Details of these phases are set out on the NHS England weight-management injections page.

From April 2026, some GP practices may prescribe tirzepatide directly under updated contract arrangements, though this is optional and availability varies. Scotland, Wales and Northern Ireland have different arrangements. If you're close to qualifying, it's worth speaking to your GP about where you fall in the phased criteria. You might also find the eligibility guide helpful for working out whether private or NHS access is the more realistic route for you.

One practical point: NHS prescriptions include wrap-around lifestyle support, which matters for long-term outcomes. Private prescriptions should also include clinical oversight, not just a dispensed pen. If you're comparing routes, that wrap-around element is worth factoring in either way.

Why cheap private Mounjaro should raise questions, not confidence

When money is tight, it's natural to search for the lowest price. The difficulty is that very low prices for tirzepatide in the UK are, in most cases, a warning sign rather than a bargain. The MHRA has repeatedly warned the public about counterfeit weight-loss pens sold through social media and websites offering these medicines without a prescription. In October 2025, enforcement teams raided what was reportedly the first illicit UK site producing fake tirzepatide pens; by that point, around 20 million doses of illegally traded weight-loss medicines worth approximately £45 million had already been seized. You can report suspect sellers and suspicious products directly at the MHRA's Yellow Card portal.

Genuine tirzepatide requires refrigerated handling throughout its supply chain, prescription from a registered prescriber, and dispensing from a GPhC-registered pharmacy. If a listing doesn't make all of those things verifiable and transparent, the medicine itself may not be genuine, and the risks of using counterfeit injectable medicines are serious. A lower sticker price that bypasses clinical assessment is not a saving in any meaningful sense. The Mounjaro pricing page explains what a legitimate private prescription typically includes, and why headline prices between providers can look so different. For broader context on whether treatment might still be an option, the weight-loss treatment overview sets out the full landscape.

If cost means you're thinking of stopping treatment you've already started

Stopping tirzepatide mid-course is a separate question from never starting it. If you're already on treatment and the cost has become unmanageable, that decision should involve your prescriber. Stopping abruptly, without a plan, often reverses gains more quickly than a gradual step-down or a planned pause with lifestyle support in place. The page on what to do if you can't afford to continue Mounjaro covers this in more detail, including what to discuss with your clinical team.

It's also worth checking whether your circumstances might now meet NHS criteria, especially given the June 2026 cohort expansion. What wasn't accessible a year ago may now be. And if you have concerns about particular side effects that are affecting your willingness to continue, our pages on how Mounjaro can affect your eyes and its effects on your cycle address some of the more specific questions people raise. Your prescriber or the clinical team listed on the clinical team page can help you work through those concerns properly.

If private treatment is something you'd like to explore when timing and cost align, a free consultation with a GPhC-registered prescriber is the place to start. There's no obligation, no fee for the clinical review itself, and no subscription. Start your free consultation when you're ready.